Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fish and Richardson
Boehringer Ingelheim
Teva
Johnson and Johnson
Covington
Healthtrust
Cerilliant
Federal Trade Commission

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,211,253

« Back to Dashboard

Which drugs does patent 9,211,253 protect, and when does it expire?

Patent 9,211,253 protects NARCAN and is included in one NDA.

This patent has fifteen patent family members in twelve countries.
Summary for Patent: 9,211,253
Title:Nasal drug products and methods of their use
Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Inventor(s): Crystal; Roger (London, GB), Weiss; Michael Brenner (New York, NY)
Assignee: Lightlake Therapeutics Inc. (New York, NY)
Application Number:14/659,472
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Delivery; Device; Use;

Drugs Protected by US Patent 9,211,253

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Adapt NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411-001 Nov 18, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,211,253

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,561,177 Nasal drug products and methods of their use ➤ Sign Up
9,629,965 Nasal drug products and methods of their use ➤ Sign Up
9,707,226 Nasal drug products and methods of their use ➤ Sign Up
9,468,747 Nasal drug products and methods of their use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Dow
Queensland Health
Daiichi Sankyo
Deloitte
McKesson
Boehringer Ingelheim
QuintilesIMS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.